Amlodipine And Atorvastatin Tablet, Film Coated
Product Images NDC 0378-4513
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Amlodipine And Atorvastatin (NDC 0378-4513). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Mylan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1. Kaplan-meier Analysis Of Composite Clinical Outcomes For Amlodipine Vs. Placebo (Image 02)
This appears to be output from a statistical analysis of some kind, likely related to a medical study involving a medication called "Amlodipine". The "Event Rate" is listed at 0.0 and there is a P-value of 0.003 and Hazard Ratio of 0.691, along with a 95% CI between 0.54 and 0.88. There are also some numerical values listed with the heading "at risk" and a time frame indicated in months. The specifics of the analysis and their implications are not clear without additional context.*
Figure 2. Effects On Primary Endpoint Of Amlodipine Vs. Placebo Across Sub-groups (Image 03)
This is a table showing the distribution of patients (male and female) based on various factors such as baseline systolic blood pressure, vessel disease, and stenosis. The table also includes the number of patients who underwent PCI (percutaneous coronary intervention) with or without stent placement. The mean sitting baseline SBP is 129 mmHg.*
Figure 3. Effect Of Atorvastatin 10 mg/day On Cumulative Incidence Of Non-fatal Myocardial Infarction Or Coronary Heart Disease Death (in Ascot-lla) (Image 04)
Figure 4. Effect Of Atorvastatin 10 mg/day On Time To Occurrence Of Major Cardiovascular Events (myocardial Infarction, Acute Chd Death, Unstable Angina, Coronary Revascularization, Or Stroke) In Cards (Image 05)
The text describes a cumulative hazard graph that shows data for a placebo and a medication called Atorvastatin. There is also information on hazard ratio (HR) and confidence intervals (0.48-0.83) for the medication. The x-axis shows time to the first primary endpoint through four years of follow up.*
Figure 5. Effect Of Atorvastatin 80 mg/day Vs. 10 mg/day On Time To Occurrence Of Major Cardiovascular Events (tnt) (Image 06)
This is a description of a clinical trial that evaluated the effects of Atorvastatin, a medication used to lower cholesterol levels, on major cardiovascular events. The table shows the percentage of subjects who experienced the event, and the graph displays the time to the first major cardiovascular endpoint in years. The study found that Atorvastatin at a dosage of 80mg reduced the risk of the event by 22% (HR 0.78, CI 0.69-0.89, P=0.0002) compared to a lower dosage of 10mg.*
Amlodipine Besylate And Atorvastatin Calcium Tablets 2.5 mg/10 mg Bottle Label (Image 07)
This is a description of a medication called Amlodipine and Atorvastatin, which is sold in the form of tablets. The tablets are produced by Viron Pharmaceuticals and have a unique NDC identification code of 0378-4513-93. The tablets are marked with the brand name Mylan and are available by prescription only. The medication is used to treat high blood pressure and high cholesterol and comes in a 30-tablet pack. The packaging includes a prompt to print the lot number, expiry date, and variable data online coding for each tablet.*
Amlodipine Besylate And Atorvastatin Calcium Tablets 2.5 mg/20 mg Bottle Label (Image 08)
Amlodipine Besylate And Atorvastatin Calcium Tablets 2.5 mg/40 mg Bottle Label (Image 09)
Amlodipine Besylate And Atorvastatin Calcium Tablets 5 mg/10 mg Bottle Label (Image 10)
This is a medication called Amlodipine and Atorvastatin Tablets, USP. Each coated tablet contains 5 mg of Amlodipine equivalent to 6.9 mg Amlodipine and 1986751 mg Atorvastatin. The recommended dosage should be obtained from the prescribing information. It should be stored at controlled room temperature between 20-25°C (68-77°F). This medication is manufactured by Mylan Pharmaceuticals Inc. in India. The packaging contains 30 tablets and the NDC number is 0378-4516-93. It must be kept out of reach of children and kept in a tightly sealed, light-resistant container. The code number is MHDRUGS25MKD/B and there is some variable data coding online available. The LOT and EXP information would be printed along with other variable data, whenever applicable.*
Amlodipine Besylate And Atorvastatin Calcium Tablets 5 mg/20 mg Bottle Label (Image 11)
Amlodipine Besylate And Atorvastatin Calcium Tablets 5 mg/40 mg Bottle Label (Image 12)
This appears to be a pharmaceutical packaging label with information such as a phone number and a product name "Ao Tablets, USP". The label also includes a prompt for printing "LOT" and "EXP" for variable data coding. There is a code number "1234567" printed at the end, along with some other numbers and symbols.*
Amlodipine Besylate And Atorvastatin Calcium Tablets 5 mg/80 mg Bottle Label (Image 13)
Amlodipine Besylate And Atorvastatin Calcium Tablets 10 mg/10 mg Bottle Label (Image 14)
This is a description of a medication called Amlodipine and Atorvastatin Tablets, USP. Each tablet contains 10mg of Amlodipine equivalent to 13.83mg of Amlodipine besylate, USP, and 80mg of Atorvastatin equivalent to 86.751mg of Atorvastatin calcium, USP. The usual dosage is not provided in the text and must be obtained from accompanying prescribing information. The medication should be kept out of reach of children and stored at 20-25°C. The tablets are manufactured by Myl Pharmaceuticals Inc. and are dispensed in a light-resistant container. The text also includes a product code, but the information on how to use it is not available.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.